CD2 and oral mucositis: In a clinical trial with patients with squamous cell carcinoma of the head and neck treated with radiotherapy, Sharma et al. [29] reported that the administration of Lactobacillus brevis CD2 reduced the incidence of grade 3 and 4 oral mucositis (52% incidence in the probiotic group versus 77% in the placebo group).